Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir vs. Entecavir for preventing liver cancer recurrence
NCT04392700Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tenofovir disoproxil fumarate in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Recurrence of HCC at 36 months. Status: unknown.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04392700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392700.